Real -world efficacy of switching to faricimab therapy in patients with longstanding neovascular age -related macular degeneration

被引：0
|
作者：
Long Phan [1 ,2 ]
Chin, Jennifer [1 ]
Hong, Thomas [1 ,2 ]
Chang, Andrew [1 ,2 ]
机构：
[1] CUREOS, Sydney, NSW, Australia
[2] Sydney Retina, Sydney, NSW, Australia
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
234
引用
收藏
页数：4
相关论文
共 50 条
  • [21] The Short-Term Efficacy and Safety of Faricimab in Refractory Neovascular Age-Related Macular Degeneration: The Real-World Experience in Taiwan
    Chi, Sheng-Chu
    Weng, Chang-Chi
    Chen, Shih-Jen
    Lin, Tai-Chi
    Chou, Yu-Bai
    Hwang, De-Kuang
    OPHTHALMOLOGICA, 2024, 247 (5-6) : 312 - 321
  • [22] The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study-6 month results
    Khanani, Arshad M.
    Aziz, Aamir A.
    Khan, Hannah
    Gupta, Ashwin
    Mojumder, Ohidul
    Saulebayeva, Aigerim
    Abbey, Ashkan M.
    Almeida, David R. P.
    Avery, Robert L.
    Banda, Himanshu K.
    Barakat, Mark R.
    Bhandari, Ramanath
    Chang, Emmanuel Y.
    Haug, Sara J.
    London, Nikolas J. S.
    Mein, Luke
    Sheth, Veeral S.
    Wolfe, Jeremy D.
    Singer, Michael A.
    Danzig, Carl J.
    EYE, 2023, 37 (17) : 3574 - 3581
  • [23] Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
    Leung, Ella H.
    Oh, Daniel J.
    Alderson, Shannon E.
    Bracy, Joshlynn
    McLeod, Mia
    Perez, Litzi, I
    Bottini, Alexander
    Yee, David Chin
    Mukkamala, Krishna
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1287 - 1293
  • [24] Clinical Outcomes Following a Switch of Therapy to Faricimab in Patients Affected by Neovascular Age-Related Macular Degeneration
    Wolfrum, Peter
    Boehm, Elsa Wilma
    Lorenz, Katrin
    Stoffelns, Bernhard
    Pfeiffer, Norbert
    Korb, Christina A.
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (02)
  • [25] Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Desideri, Lorenzo Ferro
    Traverso, Carlo Enrico
    Nicolo, Massimo
    Munk, Marion R.
    PHARMACEUTICS, 2023, 15 (05)
  • [26] Use of Faricimab in the real-world clinical practice for non-treatment naive neovascular age-related macular degeneration patients
    Tran, Donald
    Trung M. Dang
    Moodie, Jonathan
    Luckie, Alan
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 51 (09): : 1020 - 1020
  • [27] 1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration
    Janmohamed, Imran Karim
    Mushtaq, Adeel
    Kabbani, Jamil
    Harrow, Simeon
    Nadarajasundaram, Aaruran
    Ata, Anibe
    Monye, Henrietta
    Jarrar, Zakariya
    Hannan, Shabeeba
    Membrey, Luke
    EYE, 2025,
  • [28] Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
    Jern, Irene
    Forsell, Sara
    Norberg, Helena
    BMJ OPEN, 2022, 12 (09):
  • [29] BUDGET IMPACT OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE RELATED DEGENERATION IN CANADA
    Buhrer, C.
    Diles, D.
    VALUE IN HEALTH, 2023, 26 (06) : S73 - S73
  • [30] Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration
    Pandit, Saagar A.
    Momenaei, Bita
    Wakabayashi, Taku
    Mansour, Hana A.
    Vemula, Sudheshna
    Durrani, Asad F.
    Pashaee, Bahram
    Kazan, Adina S.
    Ho, Allen C.
    Klufas, Michael
    Regillo, Carl
    Yonekawa, Yoshihiro
    Hsu, Jason
    Kuriyan, Ajay
    Chiang, Allen
    OPHTHALMOLOGY RETINA, 2024, 8 (04): : 360 - 366
12345